IL-JSSI
Jet Support Services, Inc. (JSSI), the leading independent provider of maintenance support and financial services to the business aviation industry, has appointed Tim Elberfeld as chief financial officer and named Ken Goodman as chief underwriting officer. Both Elberfeld and Goodman will report directly to the CEO, Neil Book.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510005978/en/
Elberfeld brings more than 20 years of experience across global businesses in all aspects of finance and accounting, including M&A and system implementations, to his new role as chief financial officer and head of information technology at JSSI.
“It is with a lot of excitement that we welcome Tim to the team as we embark on our next chapter of growth and transformation at JSSI. Tim’s experience and leadership has already been felt across the organization,” said Neil Book, chairman and CEO of JSSI.
Elberfeld was previously at TransUnion for 10 years, an information, risk and fraud prevention solutions company, where he held leadership roles including chief accounting officer and chief financial officer of the Africa region, based in Johannesburg, South Africa. Elberfeld began his career at PricewaterhouseCoopers (PwC) where he led cross-border engagements for clients in their execution of complex acquisitions, divestitures, and carve-outs for over 12 years, including a multi-year secondment in Zurich, Switzerland.
“I am excited to join JSSI and be part of an organization that works hard every day to deliver world-class solutions and support to its diverse customer base. I look forward to working with my colleagues at JSSI to help drive the business into the future,” said Elberfeld.
After serving as JSSI’s chief financial officer for six years, Goodman will now lead the organization’s pricing, asset management and insurance efforts as chief underwriting officer. Goodman brings more than 20 years of executive financial experience, having formerly been senior vice president of financial planning and analysis at NetJets and vice president of finance for real estate and stores at Victoria’s Secret.
“I am grateful to Ken for the tremendous job he’s done as CFO over these last six years. I’m excited to see him take on this new challenge and apply his industry knowledge to take our underwriting organization to the next level. He brings a sense of focus, precision and clarity to the critical pricing process, which will ultimately improve the service and value we deliver for our hourly cost maintenance clients,” added Book.
ENDS
About Jet Support Services, Inc.
For more than 30 years, Jet Support Services, Inc. (JSSI), has been the leading independent provider of maintenance support and financial services to the business aviation industry. JSSI maintains more than 2,000 aircraft across the globe, serving customers through an infrastructure of certified technical advisors. JSSI leverages this technical knowledge, experience, buying power and data to provide support at every stage of the aircraft life cycle.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005978/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altris and Draslovka Partner to Scale Europe’s First Sodium-Ion Battery Technology Supply Chain15.1.2026 14:00:00 CET | Press release
Altris, a Swedish sodium-ion battery developer, and Draslovka, a global leader in specialty chemicals, have entered a strategic partnership to build Europe’s first industrial-scale sodium-ion cathode value chain. Under the comprehensive agreement that includes a total 19.3 MEUR in-kind investment by Draslovka in Altris, the two companies will scale fully connected production of Altris’ patented sodium-ion cathode active material (CAM) at Draslovka’s facility in Kolín, Czech Republic, supplying up to 350 tonnes of CAM annually. Draslovka and Altris are partnering to convert an existing line at Draslovka’s Kolín facility for production of Altris’ sodium-ion CAM, enabling rapid time-to-market and capital-efficient scale-up. Once ramped, the line will support production of up to 350 tonnes annually – a European-controlled supply equivalent to around 175 MWh of sodium-ion cell capacity. As part of the agreement, Draslovka is making a new in‑kind 19.3 MEUR strategic investment in Altris to c
CPP Investments Increases Commitment to Canadian Market through Northleaf Capital Partners15.1.2026 14:00:00 CET | Press release
Canada Pension Plan Investment Board (CPP Investments) and Northleaf Capital Partners (Northleaf) today announced a significant expansion of their longstanding Canadian investment partnership, supporting the growth and scaling of domestic private companies. CPP Investments has committed to invest an additional C$750 million through its established Canadian mid-market program managed by Northleaf, bringing CPP Investments’ cumulative commitments to the manager to more than C$3 billion since inception. The customized mandate focuses on maximizing net returns through a diversified strategy that includes primary fund commitments to small and mid-market Canadian buyout funds, secondary investments, and direct co-investments focused on the domestic market. “There are compelling investment opportunities in the Canadian market, and our two-decade long partnership with Northleaf has proven to be an effective and scalable way to invest in homegrown businesses with patient, long-term capital,” sa
Vantage Data Centers Completes £200M Tap of Existing £600M Industry-First EMEA Data Center Asset-Backed Securitization (ABS) and Adds New £54M Class B Tranche15.1.2026 14:00:00 CET | Press release
Financing will support the company’s expansion across EMEA to keep pace with AI and cloud demand Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised an additional £254 million in securitized term notes. £200 million was raised through a tap of the existing Class A-2 Notes while £54 million was raised from the new Class B Tranche. This builds on Vantage’s debut public issuance in 2024 raising £600 million, which was the first-ever EMEA data center ABS completed in sterling. The Class A-2 Notes are rated A-, A (low) and A by Standard & Poor’s, Morningstar DBRS and Scope Ratings, respectively. The Class B Notes are rated BBB- by Standard & Poor’s and BBB by Morningstar DBRS and Scope Ratings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115777091/en/ Vantage’s 148MW Cardiff, Wales, campus is one of Europe’s largest hyperscale data center campuses. The new notes
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials15.1.2026 13:57:00 CET | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/ Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC. The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements. “Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Dere
InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease15.1.2026 13:30:00 CET | Press release
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™ discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom